DK2262807T3 - NOVEL tyrosine kinase inhibitors - Google Patents
NOVEL tyrosine kinase inhibitors Download PDFInfo
- Publication number
- DK2262807T3 DK2262807T3 DK09721981.0T DK09721981T DK2262807T3 DK 2262807 T3 DK2262807 T3 DK 2262807T3 DK 09721981 T DK09721981 T DK 09721981T DK 2262807 T3 DK2262807 T3 DK 2262807T3
- Authority
- DK
- Denmark
- Prior art keywords
- alkyl
- oxo
- mmol
- dihydropyridin
- ethyl
- Prior art date
Links
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims description 124
- -1 heterocyclyloxyalkyl Chemical group 0.000 claims description 109
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 56
- 239000001257 hydrogen Substances 0.000 claims description 51
- 229910052739 hydrogen Inorganic materials 0.000 claims description 51
- 125000000217 alkyl group Chemical group 0.000 claims description 50
- 230000000694 effects Effects 0.000 claims description 46
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 42
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 42
- 208000035475 disorder Diseases 0.000 claims description 41
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims description 35
- 125000001424 substituent group Chemical group 0.000 claims description 35
- 125000001072 heteroaryl group Chemical group 0.000 claims description 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 23
- 125000003545 alkoxy group Chemical group 0.000 claims description 22
- 125000004432 carbon atom Chemical group C* 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 22
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 18
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 10
- 125000003107 substituted aryl group Chemical group 0.000 claims description 10
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 8
- 208000010962 ALK-positive anaplastic large cell lymphoma Diseases 0.000 claims description 7
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 7
- 208000005017 glioblastoma Diseases 0.000 claims description 7
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims description 6
- 206010029260 Neuroblastoma Diseases 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 239000000969 carrier Substances 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 5
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 5
- 201000003803 Inflammatory myofibroblastic tumor Diseases 0.000 claims description 4
- 206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 claims description 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 4
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 4
- 125000005335 azido alkyl group Chemical group 0.000 claims description 4
- 125000005518 carboxamido group Chemical group 0.000 claims description 4
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 2
- 125000004971 nitroalkyl group Chemical group 0.000 claims description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims description 2
- 125000001302 tertiary amino group Chemical group 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 14
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims 1
- DRZDPLDMEHBZDN-UHFFFAOYSA-N 2,3-dihydroisoindol-5-one Chemical compound O=C1C=CC2=CNCC2=C1 DRZDPLDMEHBZDN-UHFFFAOYSA-N 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 227
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 195
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 144
- 239000000243 solution Substances 0.000 description 138
- 238000005160 1H NMR spectroscopy Methods 0.000 description 98
- 235000019439 ethyl acetate Nutrition 0.000 description 95
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 93
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 93
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 86
- 238000000034 method Methods 0.000 description 75
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 71
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 71
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 65
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 64
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 57
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 56
- 239000003921 oil Substances 0.000 description 56
- 235000019198 oils Nutrition 0.000 description 55
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 54
- 239000000284 extract Substances 0.000 description 53
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 51
- 239000002552 dosage form Substances 0.000 description 49
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 43
- 229960001866 silicon dioxide Drugs 0.000 description 43
- 239000007787 solid Substances 0.000 description 43
- 206010028980 Neoplasm Diseases 0.000 description 42
- 239000000741 silica gel Substances 0.000 description 42
- 229910002027 silica gel Inorganic materials 0.000 description 42
- 239000010779 crude oil Substances 0.000 description 41
- 238000002360 preparation method Methods 0.000 description 41
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 37
- 238000002560 therapeutic procedure Methods 0.000 description 34
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 33
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 32
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 30
- 239000011541 reaction mixture Substances 0.000 description 30
- 125000003118 aryl group Chemical group 0.000 description 29
- 239000004480 active ingredient Substances 0.000 description 27
- 229910052757 nitrogen Inorganic materials 0.000 description 27
- 230000005764 inhibitory process Effects 0.000 description 24
- 239000007788 liquid Substances 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 22
- 239000003795 chemical substances by application Substances 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- 101150111783 NTRK1 gene Proteins 0.000 description 20
- 239000003814 drug Substances 0.000 description 20
- 238000003786 synthesis reaction Methods 0.000 description 20
- 238000011282 treatment Methods 0.000 description 20
- 108091000080 Phosphotransferase Proteins 0.000 description 18
- GOOHAUXETOMSMM-GSVOUGTGSA-N R-propylene oxide Chemical compound C[C@@H]1CO1 GOOHAUXETOMSMM-GSVOUGTGSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 102000020233 phosphotransferase Human genes 0.000 description 18
- 241000282414 Homo sapiens Species 0.000 description 17
- 125000004414 alkyl thio group Chemical group 0.000 description 17
- 201000011510 cancer Diseases 0.000 description 17
- 238000001914 filtration Methods 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 17
- 150000003254 radicals Chemical class 0.000 description 17
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 16
- 230000000069 prophylactic effect Effects 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 14
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 14
- 108010025020 Nerve Growth Factor Proteins 0.000 description 14
- 230000004927 fusion Effects 0.000 description 13
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 13
- 230000011664 signaling Effects 0.000 description 13
- 102000015336 Nerve Growth Factor Human genes 0.000 description 12
- 150000001540 azides Chemical class 0.000 description 12
- 239000003054 catalyst Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 229940053128 nerve growth factor Drugs 0.000 description 12
- 229910052763 palladium Inorganic materials 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 125000003396 thiol group Chemical class [H]S* 0.000 description 12
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 11
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 11
- 125000002252 acyl group Chemical group 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 11
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 11
- 229940124597 therapeutic agent Drugs 0.000 description 11
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 10
- 150000001412 amines Chemical class 0.000 description 10
- 235000011114 ammonium hydroxide Nutrition 0.000 description 10
- 238000004587 chromatography analysis Methods 0.000 description 10
- 238000013270 controlled release Methods 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 9
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 9
- 229910017974 NH40H Inorganic materials 0.000 description 9
- 125000004442 acylamino group Chemical group 0.000 description 9
- 125000005110 aryl thio group Chemical group 0.000 description 9
- 125000004122 cyclic group Chemical group 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 125000001183 hydrocarbyl group Chemical group 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- 125000005415 substituted alkoxy group Chemical group 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 8
- 101100262697 Mus musculus Axl gene Proteins 0.000 description 8
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 8
- 125000004423 acyloxy group Chemical group 0.000 description 8
- 125000001931 aliphatic group Chemical group 0.000 description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 8
- 125000004104 aryloxy group Chemical group 0.000 description 8
- 239000007884 disintegrant Substances 0.000 description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 8
- 239000006186 oral dosage form Substances 0.000 description 8
- 150000003384 small molecules Chemical class 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 7
- 102000003746 Insulin Receptor Human genes 0.000 description 7
- 108010001127 Insulin Receptor Proteins 0.000 description 7
- 229930194542 Keto Natural products 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 108700020796 Oncogene Proteins 0.000 description 7
- 206010060862 Prostate cancer Diseases 0.000 description 7
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 7
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 125000000468 ketone group Chemical group 0.000 description 7
- 238000007726 management method Methods 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 239000012046 mixed solvent Substances 0.000 description 7
- 239000006201 parenteral dosage form Substances 0.000 description 7
- 102000005162 pleiotrophin Human genes 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 125000005323 thioketone group Chemical group 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- BTDSUQRCVUBHNX-YFKPBYRVSA-N (2s)-1-(3-chlorothiophen-2-yl)propan-2-amine Chemical compound C[C@H](N)CC=1SC=CC=1Cl BTDSUQRCVUBHNX-YFKPBYRVSA-N 0.000 description 6
- IDUAQSPIDXGMKI-LURJTMIESA-N (2s)-1-(furan-2-yl)propan-2-amine Chemical compound C[C@H](N)CC1=CC=CO1 IDUAQSPIDXGMKI-LURJTMIESA-N 0.000 description 6
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 6
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- 108010092801 Midkine Proteins 0.000 description 6
- 102100030335 Midkine Human genes 0.000 description 6
- 101150056950 Ntrk2 gene Proteins 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 239000012230 colorless oil Substances 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 231100000590 oncogenic Toxicity 0.000 description 6
- 230000002246 oncogenic effect Effects 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 6
- MJRDCJBNRNAXIK-RGMNGODLSA-N (2s)-1-thiophen-2-ylpropan-2-amine;hydrochloride Chemical compound Cl.C[C@H](N)CC1=CC=CS1 MJRDCJBNRNAXIK-RGMNGODLSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 101001004391 Drosophila melanogaster Protein jim lovell Proteins 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 101150117329 NTRK3 gene Proteins 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 208000024770 Thyroid neoplasm Diseases 0.000 description 5
- 125000003282 alkyl amino group Chemical group 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 125000000392 cycloalkenyl group Chemical group 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000036210 malignancy Effects 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 5
- IIEKGEWJHCOCNF-SCSAIBSYSA-N (2r)-1-(2,3,5,6-tetrafluorophenyl)propan-2-ol Chemical compound C[C@@H](O)CC1=C(F)C(F)=CC(F)=C1F IIEKGEWJHCOCNF-SCSAIBSYSA-N 0.000 description 4
- WKTRHSVNRZODEY-RXMQYKEDSA-N (2r)-1-(2,3,5-trifluorophenyl)propan-2-ol Chemical compound C[C@@H](O)CC1=CC(F)=CC(F)=C1F WKTRHSVNRZODEY-RXMQYKEDSA-N 0.000 description 4
- WMKLPGQIBSLFFE-ZCFIWIBFSA-N (2r)-1-(2,3-difluoro-5,6-dimethoxyphenyl)propan-2-ol Chemical compound COC1=CC(F)=C(F)C(C[C@@H](C)O)=C1OC WMKLPGQIBSLFFE-ZCFIWIBFSA-N 0.000 description 4
- RPYWIZDAMGNPJB-MRVPVSSYSA-N (2r)-1-(2,5-dimethoxyphenyl)propan-2-ol Chemical compound COC1=CC=C(OC)C(C[C@@H](C)O)=C1 RPYWIZDAMGNPJB-MRVPVSSYSA-N 0.000 description 4
- IZLFCDFSMLAYGR-SECBINFHSA-N (2r)-1-(2-ethylphenyl)propan-2-ol Chemical compound CCC1=CC=CC=C1C[C@@H](C)O IZLFCDFSMLAYGR-SECBINFHSA-N 0.000 description 4
- KIYWCFHLUIBVMY-ZCFIWIBFSA-N (2r)-1-(3,4-difluoro-2-methylphenyl)propan-2-ol Chemical compound C[C@@H](O)CC1=CC=C(F)C(F)=C1C KIYWCFHLUIBVMY-ZCFIWIBFSA-N 0.000 description 4
- UCDRLTIDEGXRGX-ZCFIWIBFSA-N (2r)-1-(3,5-difluoro-2-methylphenyl)propan-2-ol Chemical compound C[C@@H](O)CC1=CC(F)=CC(F)=C1C UCDRLTIDEGXRGX-ZCFIWIBFSA-N 0.000 description 4
- UHENTRIIZXMDCC-MRVPVSSYSA-N (2r)-1-(5-chloro-2-methylphenyl)propan-2-ol Chemical compound C[C@@H](O)CC1=CC(Cl)=CC=C1C UHENTRIIZXMDCC-MRVPVSSYSA-N 0.000 description 4
- NCFRFBOXIPIYAO-SECBINFHSA-N (2r)-1-(5-methoxy-2-methylphenyl)propan-2-ol Chemical compound COC1=CC=C(C)C(C[C@@H](C)O)=C1 NCFRFBOXIPIYAO-SECBINFHSA-N 0.000 description 4
- TVEZJSIMQALGPR-MRVPVSSYSA-N (2r)-1-[2-methyl-5-(trifluoromethyl)phenyl]propan-2-ol Chemical compound C[C@@H](O)CC1=CC(C(F)(F)F)=CC=C1C TVEZJSIMQALGPR-MRVPVSSYSA-N 0.000 description 4
- ZHQYFXHHMZFJDL-SNVBAGLBSA-N (2r)-1-[5-(dimethylamino)-2-methylphenyl]propan-2-ol Chemical compound C[C@@H](O)CC1=CC(N(C)C)=CC=C1C ZHQYFXHHMZFJDL-SNVBAGLBSA-N 0.000 description 4
- VFLJOFXKRGVFBK-LURJTMIESA-N (2s)-1-(2,3-dichlorophenyl)propan-2-amine Chemical compound C[C@H](N)CC1=CC=CC(Cl)=C1Cl VFLJOFXKRGVFBK-LURJTMIESA-N 0.000 description 4
- HTEBKXXBGSCPMS-LURJTMIESA-N (2s)-1-(2,5-dichlorophenyl)propan-2-amine Chemical compound C[C@H](N)CC1=CC(Cl)=CC=C1Cl HTEBKXXBGSCPMS-LURJTMIESA-N 0.000 description 4
- HTACZPWEZNGXGV-LURJTMIESA-N (2s)-1-(2-bromo-5-fluorophenyl)propan-2-amine Chemical compound C[C@H](N)CC1=CC(F)=CC=C1Br HTACZPWEZNGXGV-LURJTMIESA-N 0.000 description 4
- BSXFIEDRPNZSEK-LURJTMIESA-N (2s)-1-(2-chloro-5-fluorophenyl)propan-2-amine Chemical compound C[C@H](N)CC1=CC(F)=CC=C1Cl BSXFIEDRPNZSEK-LURJTMIESA-N 0.000 description 4
- JKSJCZONSZZHGB-ZETCQYMHSA-N (2s)-1-(3-methylthiophen-2-yl)propan-2-amine Chemical compound C[C@H](N)CC=1SC=CC=1C JKSJCZONSZZHGB-ZETCQYMHSA-N 0.000 description 4
- HEXFVXVARZAQBI-QMMMGPOBSA-N (2s)-1-(5-fluoro-2-methylphenyl)propan-2-amine Chemical compound C[C@H](N)CC1=CC(F)=CC=C1C HEXFVXVARZAQBI-QMMMGPOBSA-N 0.000 description 4
- ADDOPDONOTWKMJ-YFKPBYRVSA-N 1-[(2s)-2-azidopropyl]-2,3,5-trifluorobenzene Chemical compound [N-]=[N+]=N[C@@H](C)CC1=CC(F)=CC(F)=C1F ADDOPDONOTWKMJ-YFKPBYRVSA-N 0.000 description 4
- FEORXWSWAKIOSY-LURJTMIESA-N 2-[(2s)-2-azidopropyl]-1-bromo-4-fluorobenzene Chemical compound [N-]=[N+]=N[C@@H](C)CC1=CC(F)=CC=C1Br FEORXWSWAKIOSY-LURJTMIESA-N 0.000 description 4
- FSJHYCTVHDXLQI-LURJTMIESA-N 2-[(2s)-2-azidopropyl]-1-chloro-4-fluorobenzene Chemical compound [N-]=[N+]=N[C@@H](C)CC1=CC(F)=CC=C1Cl FSJHYCTVHDXLQI-LURJTMIESA-N 0.000 description 4
- YFZAVGZOMHPNNF-QMMMGPOBSA-N 2-[(2s)-2-azidopropyl]-1-methyl-4-(trifluoromethyl)benzene Chemical compound [N-]=[N+]=N[C@@H](C)CC1=CC(C(F)(F)F)=CC=C1C YFZAVGZOMHPNNF-QMMMGPOBSA-N 0.000 description 4
- BDLHHYYXSAOGNF-KRWDZBQOSA-N 2-[4-[[(2S)-1-(furan-2-yl)propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-6-(2-pyrrolidin-1-ylethyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3CN(CCN4CCCC4)C(=O)C=3C=C2N=1)C1=CC=CO1 BDLHHYYXSAOGNF-KRWDZBQOSA-N 0.000 description 4
- CTFAJHRIVKHDQJ-JTQLQIEISA-N 3-[(2s)-2-azidopropyl]-n,n,4-trimethylaniline Chemical compound [N-]=[N+]=N[C@@H](C)CC1=CC(N(C)C)=CC=C1C CTFAJHRIVKHDQJ-JTQLQIEISA-N 0.000 description 4
- PGTIXTMEYKATRQ-UHFFFAOYSA-N 3h-pyrrolo[3,4-f]benzimidazole-5,7-dione Chemical compound C1=C2C(=O)NC(=O)C2=CC2=C1N=CN2 PGTIXTMEYKATRQ-UHFFFAOYSA-N 0.000 description 4
- RPJXLEZOFUNGNZ-UHFFFAOYSA-N 5-methoxy-2-methylaniline Chemical compound COC1=CC=C(C)C(N)=C1 RPJXLEZOFUNGNZ-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 102100022678 Nucleophosmin Human genes 0.000 description 4
- 108010025568 Nucleophosmin Proteins 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 4
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 4
- 230000001594 aberrant effect Effects 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 239000007894 caplet Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 201000005619 esophageal carcinoma Diseases 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 238000000021 kinase assay Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- QSRRZKPKHJHIRB-UHFFFAOYSA-N methyl 4-[(2,5-dichloro-4-methylthiophen-3-yl)sulfonylamino]-2-hydroxybenzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1NS(=O)(=O)C1=C(Cl)SC(Cl)=C1C QSRRZKPKHJHIRB-UHFFFAOYSA-N 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 208000004296 neuralgia Diseases 0.000 description 4
- 208000021722 neuropathic pain Diseases 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 125000000547 substituted alkyl group Chemical group 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 201000002510 thyroid cancer Diseases 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- IYHLRAUXPBWMSR-ZCFIWIBFSA-N (2r)-1-(2-bromo-5-fluorophenyl)propan-2-ol Chemical compound C[C@@H](O)CC1=CC(F)=CC=C1Br IYHLRAUXPBWMSR-ZCFIWIBFSA-N 0.000 description 3
- NCCQDHNIFWWNNG-ZCFIWIBFSA-N (2r)-1-(2-chloro-5-fluorophenyl)propan-2-ol Chemical compound C[C@@H](O)CC1=CC(F)=CC=C1Cl NCCQDHNIFWWNNG-ZCFIWIBFSA-N 0.000 description 3
- RGIYNNJMHXWMKP-SSDOTTSWSA-N (2r)-1-(5-fluoro-2-methoxyphenyl)propan-2-ol Chemical compound COC1=CC=C(F)C=C1C[C@@H](C)O RGIYNNJMHXWMKP-SSDOTTSWSA-N 0.000 description 3
- SQVBTODMDVRLDB-BYPYZUCNSA-N (2s)-1-(2,3,5,6-tetrafluorophenyl)propan-2-amine Chemical compound C[C@H](N)CC1=C(F)C(F)=CC(F)=C1F SQVBTODMDVRLDB-BYPYZUCNSA-N 0.000 description 3
- RJQCHFYBELZAFS-YFKPBYRVSA-N (2s)-1-(2,3,5-trifluorophenyl)propan-2-amine Chemical compound C[C@H](N)CC1=CC(F)=CC(F)=C1F RJQCHFYBELZAFS-YFKPBYRVSA-N 0.000 description 3
- ZMTSBNRQPFKKSC-VIFPVBQESA-N (2s)-1-(2-ethylphenyl)propan-2-amine Chemical compound CCC1=CC=CC=C1C[C@H](C)N ZMTSBNRQPFKKSC-VIFPVBQESA-N 0.000 description 3
- ZEMQBDFHXOOXLY-VIFPVBQESA-N (2s)-1-(2-methylphenyl)propan-2-amine Chemical compound C[C@H](N)CC1=CC=CC=C1C ZEMQBDFHXOOXLY-VIFPVBQESA-N 0.000 description 3
- BSCVBWJNWZTZAQ-LURJTMIESA-N (2s)-1-(3,4-difluoro-2-methylphenyl)propan-2-amine Chemical compound C[C@H](N)CC1=CC=C(F)C(F)=C1C BSCVBWJNWZTZAQ-LURJTMIESA-N 0.000 description 3
- XUNGKTYXCMLCRM-LURJTMIESA-N (2s)-1-(3,5-difluoro-2-methylphenyl)propan-2-amine Chemical compound C[C@H](N)CC1=CC(F)=CC(F)=C1C XUNGKTYXCMLCRM-LURJTMIESA-N 0.000 description 3
- VAIGTXVYCTVDNP-ZETCQYMHSA-N (2s)-1-(3-fluoro-2-methylphenyl)propan-2-amine Chemical compound C[C@H](N)CC1=CC=CC(F)=C1C VAIGTXVYCTVDNP-ZETCQYMHSA-N 0.000 description 3
- UPBCBGGFARWMIM-LURJTMIESA-N (2s)-1-(3-methoxythiophen-2-yl)propan-2-amine Chemical compound COC=1C=CSC=1C[C@H](C)N UPBCBGGFARWMIM-LURJTMIESA-N 0.000 description 3
- SPUZCOUJPWSYHA-QMMMGPOBSA-N (2s)-1-(4-fluoro-2-methylphenyl)propan-2-amine Chemical compound C[C@H](N)CC1=CC=C(F)C=C1C SPUZCOUJPWSYHA-QMMMGPOBSA-N 0.000 description 3
- VIAYKRMSIOXQEH-QMMMGPOBSA-N (2s)-1-(5-chloro-2-methylphenyl)propan-2-amine Chemical compound C[C@H](N)CC1=CC(Cl)=CC=C1C VIAYKRMSIOXQEH-QMMMGPOBSA-N 0.000 description 3
- BVVSXTDDJLGTFX-QMMMGPOBSA-N (2s)-1-[2-methyl-5-(trifluoromethyl)phenyl]propan-2-amine Chemical compound C[C@H](N)CC1=CC(C(F)(F)F)=CC=C1C BVVSXTDDJLGTFX-QMMMGPOBSA-N 0.000 description 3
- FLVCMMRPNZCHPC-UHFFFAOYSA-N 1,5-difluoro-2-methyl-3-nitrobenzene Chemical compound CC1=C(F)C=C(F)C=C1[N+]([O-])=O FLVCMMRPNZCHPC-UHFFFAOYSA-N 0.000 description 3
- IGRYCLAUZIQZRF-UHFFFAOYSA-N 1,5-difluoro-3-iodo-2-(trifluoromethyl)benzene Chemical compound FC1=CC(F)=C(C(F)(F)F)C(I)=C1 IGRYCLAUZIQZRF-UHFFFAOYSA-N 0.000 description 3
- AKWRGQLQFYKOAV-UHFFFAOYSA-N 1,5-difluoro-3-iodo-2-methylbenzene Chemical compound CC1=C(F)C=C(F)C=C1I AKWRGQLQFYKOAV-UHFFFAOYSA-N 0.000 description 3
- NBCIJKDVDUENJY-UHFFFAOYSA-N 2-(4-chloro-2-oxo-1H-pyridin-3-yl)-6-(2-pyrrolidin-1-ylethyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C1=CNC(=O)C(C=2NC3=CC=4C(=O)N(CCN5CCCC5)CC=4C=C3N=2)=C1Cl NBCIJKDVDUENJY-UHFFFAOYSA-N 0.000 description 3
- BMHNLVBEDWEINE-SFHVURJKSA-N 2-[2-oxo-4-[[(2S)-1-thiophen-2-ylpropan-2-yl]amino]-1H-pyridin-3-yl]-6-(3-pyrrolidin-1-ylpropyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3C(=O)N(CCCN4CCCC4)CC=3C=C2N=1)C1=CC=CS1 BMHNLVBEDWEINE-SFHVURJKSA-N 0.000 description 3
- BFMVTJYTZHNIEG-KRWDZBQOSA-N 2-[4-[[(2S)-1-(2-bromo-5-fluorophenyl)propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-6-(2-pyrrolidin-1-ylethyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3C(=O)N(CCN4CCCC4)CC=3C=C2N=1)C1=CC(F)=CC=C1Br BFMVTJYTZHNIEG-KRWDZBQOSA-N 0.000 description 3
- FKRCKCKSZRUPHS-UHFFFAOYSA-N 3,5-difluoro-2-methylaniline Chemical compound CC1=C(N)C=C(F)C=C1F FKRCKCKSZRUPHS-UHFFFAOYSA-N 0.000 description 3
- OFGYWTWGNICTGT-JTQLQIEISA-N 3-[(2s)-2-aminopropyl]-n,n,4-trimethylaniline Chemical compound C[C@H](N)CC1=CC(N(C)C)=CC=C1C OFGYWTWGNICTGT-JTQLQIEISA-N 0.000 description 3
- 101150023956 ALK gene Proteins 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 208000000094 Chronic Pain Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 3
- 229910004373 HOAc Inorganic materials 0.000 description 3
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 3
- 101000850794 Homo sapiens Tropomyosin alpha-3 chain Proteins 0.000 description 3
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 description 3
- 206010020649 Hyperkeratosis Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010065390 Inflammatory pain Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 235000019483 Peanut oil Nutrition 0.000 description 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 101150077555 Ret gene Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- JIMRUZHVLCOLBW-ZETCQYMHSA-N [(2s)-1-thiophen-2-ylpropan-2-yl] methanesulfonate Chemical compound CS(=O)(=O)O[C@@H](C)CC1=CC=CS1 JIMRUZHVLCOLBW-ZETCQYMHSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 3
- 230000003305 autocrine Effects 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000006806 disease prevention Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000003596 drug target Substances 0.000 description 3
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 3
- 201000004101 esophageal cancer Diseases 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthene Chemical compound C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000003463 hyperproliferative effect Effects 0.000 description 3
- 206010021198 ichthyosis Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 150000003951 lactams Chemical class 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 239000000312 peanut oil Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical class [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 150000003335 secondary amines Chemical class 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 3
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000005017 substituted alkenyl group Chemical group 0.000 description 3
- 125000004426 substituted alkynyl group Chemical group 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229930192474 thiophene Natural products 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JPZFNNPAQDWMGC-VIFPVBQESA-N (2s)-1-(5-methoxy-2-methylphenyl)propan-2-amine Chemical compound COC1=CC=C(C)C(C[C@H](C)N)=C1 JPZFNNPAQDWMGC-VIFPVBQESA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- HVRUGFJYCAFAAN-UHFFFAOYSA-N 1-bromo-2-ethylbenzene Chemical compound CCC1=CC=CC=C1Br HVRUGFJYCAFAAN-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- UWMOORJRTNDGHI-UHFFFAOYSA-N 2-(4-chloro-2-oxo-1H-pyridin-3-yl)-6-(3-pyrrolidin-1-ylpropyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one dihydrochloride Chemical compound Cl.Cl.C1=CNC(=O)C(C=2NC3=CC=4CN(CCCN5CCCC5)C(=O)C=4C=C3N=2)=C1Cl UWMOORJRTNDGHI-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- YXMBORNKPHDCQA-KRWDZBQOSA-N 2-[2-oxo-4-[[(2S)-1-thiophen-2-ylpropan-2-yl]amino]-1H-pyridin-3-yl]-6-(2-pyrrolidin-1-ylethyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3C(=O)N(CCN4CCCC4)CC=3C=C2N=1)C1=CC=CS1 YXMBORNKPHDCQA-KRWDZBQOSA-N 0.000 description 2
- NLCYNRKJSTXVMP-UHFFFAOYSA-N 2-[4-[1-(3,5-dimethyl-1,2-oxazol-4-yl)propan-2-ylamino]-2-oxo-1H-pyridin-3-yl]-6-(3-pyrrolidin-1-ylpropyl)-3H-pyrrolo[3,4-f]benzimidazole-5,7-dione Chemical compound C1=CNC(=O)C(C=2NC3=CC=4C(=O)N(CCCN5CCCC5)C(=O)C=4C=C3N=2)=C1NC(C)CC=1C(C)=NOC=1C NLCYNRKJSTXVMP-UHFFFAOYSA-N 0.000 description 2
- BLSNKNDWYITKGB-UHFFFAOYSA-N 2-[4-[1-(5-chlorothiophen-2-yl)propan-2-ylamino]-2-oxo-1H-pyridin-3-yl]-6-(3-pyrrolidin-1-ylpropyl)-3H-pyrrolo[3,4-f]benzimidazole-5,7-dione Chemical compound C1=CNC(=O)C(C=2NC3=CC=4C(=O)N(CCCN5CCCC5)C(=O)C=4C=C3N=2)=C1NC(C)CC1=CC=C(Cl)S1 BLSNKNDWYITKGB-UHFFFAOYSA-N 0.000 description 2
- NWMBFLMHAGXQFP-PPHZAIPVSA-N 2-[4-[[(1R,2S)-1-hydroxy-1-phenylpropan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-6-(3-pyrrolidin-1-ylpropyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound N([C@@H](C)[C@H](O)C=1C=CC=CC=1)C=1C=CNC(=O)C=1C(NC1=CC=2C3=O)=NC1=CC=2CN3CCCN1CCCC1 NWMBFLMHAGXQFP-PPHZAIPVSA-N 0.000 description 2
- JCVSLSPOLHPFSZ-KRWDZBQOSA-N 2-[4-[[(2S)-1-(2-chloro-5-fluorophenyl)propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-6-(2-pyrrolidin-1-ylethyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3C(=O)N(CCN4CCCC4)CC=3C=C2N=1)C1=CC(F)=CC=C1Cl JCVSLSPOLHPFSZ-KRWDZBQOSA-N 0.000 description 2
- NVVWDIDODAINMW-IBGZPJMESA-N 2-[4-[[(2S)-1-(5-chloro-2-methylphenyl)propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-6-(2-pyrrolidin-1-ylethyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C[C@@H](Cc1cc(Cl)ccc1C)Nc1cc[nH]c(=O)c1-c1nc2cc3CN(CCN4CCCC4)C(=O)c3cc2[nH]1 NVVWDIDODAINMW-IBGZPJMESA-N 0.000 description 2
- XPJBSEGGNAOHMI-UHFFFAOYSA-N 2-[4-[[1-(4-fluorophenyl)-2-methylpropan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-6-(3-pyrrolidin-1-ylpropyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C1=CNC(=O)C(C=2NC3=CC=4C(=O)N(CCCN5CCCC5)CC=4C=C3N=2)=C1NC(C)(C)CC1=CC=C(F)C=C1 XPJBSEGGNAOHMI-UHFFFAOYSA-N 0.000 description 2
- QBLWQMOXRDHSFJ-UHFFFAOYSA-N 2-[4-[methyl(1-thiophen-2-ylpropan-2-yl)amino]-2-oxo-1H-pyridin-3-yl]-6-(3-pyrrolidin-1-ylpropyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C1=CNC(=O)C(C=2NC3=CC=4C(=O)N(CCCN5CCCC5)CC=4C=C3N=2)=C1N(C)C(C)CC1=CC=CS1 QBLWQMOXRDHSFJ-UHFFFAOYSA-N 0.000 description 2
- GUPVYQLEPFXUML-UHFFFAOYSA-N 2-[4-[methyl(1-thiophen-2-ylpropan-2-yl)amino]-2-oxo-1H-pyridin-3-yl]-6-(3-pyrrolidin-1-ylpropyl)-3H-pyrrolo[3,4-f]benzimidazole-5,7-dione Chemical compound C1=CNC(=O)C(C=2NC3=CC=4C(=O)N(CCCN5CCCC5)C(=O)C=4C=C3N=2)=C1N(C)C(C)CC1=CC=CS1 GUPVYQLEPFXUML-UHFFFAOYSA-N 0.000 description 2
- UWOIDOQAQPUVOH-UHFFFAOYSA-N 2-bromo-1,3-dichlorobenzene Chemical compound ClC1=CC=CC(Cl)=C1Br UWOIDOQAQPUVOH-UHFFFAOYSA-N 0.000 description 2
- MIHFMTLIZXCMMH-UHFFFAOYSA-N 2-iodo-4-methoxy-1-methylbenzene Chemical compound COC1=CC=C(C)C(I)=C1 MIHFMTLIZXCMMH-UHFFFAOYSA-N 0.000 description 2
- WRXNJTBODVGDRY-UHFFFAOYSA-N 2-pyrrolidin-1-ylethanamine Chemical compound NCCN1CCCC1 WRXNJTBODVGDRY-UHFFFAOYSA-N 0.000 description 2
- XTYNIPUFKBBALX-UHFFFAOYSA-N 3-chloro-1h-pyridin-2-one Chemical compound OC1=NC=CC=C1Cl XTYNIPUFKBBALX-UHFFFAOYSA-N 0.000 description 2
- PQXCTCPXPUVRAN-UHFFFAOYSA-N 3-iodo-n,n,4-trimethylaniline Chemical compound CN(C)C1=CC=C(C)C(I)=C1 PQXCTCPXPUVRAN-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- KAXKHWQURACVTO-UHFFFAOYSA-N 5,6-diamino-2,3-dihydroisoindol-1-one Chemical compound C1=C(N)C(N)=CC2=C1C(=O)NC2 KAXKHWQURACVTO-UHFFFAOYSA-N 0.000 description 2
- SEPDFZDBBWCNME-UHFFFAOYSA-N 5,6-diamino-2-[2-(dimethylamino)ethyl]isoindole-1,3-dione Chemical compound NC1=C(N)C=C2C(=O)N(CCN(C)C)C(=O)C2=C1 SEPDFZDBBWCNME-UHFFFAOYSA-N 0.000 description 2
- UZRYVWQIMADIMF-UHFFFAOYSA-N 5,6-diamino-4-chloro-2-(1-methylpiperidin-4-yl)isoindole-1,3-dione Chemical compound C1CN(C)CCC1N1C(=O)C2=C(Cl)C(N)=C(N)C=C2C1=O UZRYVWQIMADIMF-UHFFFAOYSA-N 0.000 description 2
- JTMNDVXBLVXWKV-UHFFFAOYSA-N 5,6-diamino-4-methyl-2-(2-pyrrolidin-1-ylethyl)isoindole-1,3-dione Chemical compound O=C1C2=CC(N)=C(N)C(C)=C2C(=O)N1CCN1CCCC1 JTMNDVXBLVXWKV-UHFFFAOYSA-N 0.000 description 2
- UGBDLRDJGPZHMA-UHFFFAOYSA-N 5-amino-2-[2-(dimethylamino)ethyl]-6-nitroisoindole-1,3-dione Chemical compound NC1=C([N+]([O-])=O)C=C2C(=O)N(CCN(C)C)C(=O)C2=C1 UGBDLRDJGPZHMA-UHFFFAOYSA-N 0.000 description 2
- LZLYFGIKYNNQDR-UHFFFAOYSA-N 5-amino-4-chloro-2-(1-methylpiperidin-4-yl)-6-nitroisoindole-1,3-dione Chemical compound C1CN(C)CCC1N1C(=O)C2=C(Cl)C(N)=C([N+]([O-])=O)C=C2C1=O LZLYFGIKYNNQDR-UHFFFAOYSA-N 0.000 description 2
- JOPWCYFGRYCBEF-UHFFFAOYSA-N 5-amino-6-nitroisoindole-1,3-dione Chemical compound C1=C([N+]([O-])=O)C(N)=CC2=C1C(=O)NC2=O JOPWCYFGRYCBEF-UHFFFAOYSA-N 0.000 description 2
- MPNGBNBNRHPHOG-IBGZPJMESA-N 6-[1-(2-ethylsulfonylethyl)piperidin-4-yl]-2-[2-oxo-4-[[(2S)-1-thiophen-2-ylpropan-2-yl]amino]-1H-pyridin-3-yl]-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C1CN(CCS(=O)(=O)CC)CCC1N1C(=O)C2=CC(NC(=N3)C=4C(NC=CC=4N[C@@H](C)CC=4SC=CC=4)=O)=C3C=C2C1 MPNGBNBNRHPHOG-IBGZPJMESA-N 0.000 description 2
- CWKJITVZPNGKNO-SFHVURJKSA-N 6-[2-(1,1-dioxo-1,4-thiazinan-4-yl)ethyl]-2-[4-[[(2S)-1-(3-methylthiophen-2-yl)propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3CN(CCN4CCS(=O)(=O)CC4)C(=O)C=3C=C2N=1)C=1SC=CC=1C CWKJITVZPNGKNO-SFHVURJKSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- BWCZEWMIBRWINO-UHFFFAOYSA-N 8-chloro-6-(1-methylpiperidin-4-yl)-2-[2-oxo-4-(1-thiophen-2-ylpropan-2-ylamino)-1H-pyridin-3-yl]-3H-pyrrolo[3,4-f]benzimidazole-5,7-dione Chemical compound C1=CNC(=O)C(C=2NC3=CC=4C(=O)N(C5CCN(C)CC5)C(=O)C=4C(Cl)=C3N=2)=C1NC(C)CC1=CC=CS1 BWCZEWMIBRWINO-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 101150095401 AURKA gene Proteins 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010058019 Cancer Pain Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000006332 Choriocarcinoma Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 101100261976 Drosophila melanogaster trk gene Proteins 0.000 description 2
- 102100027100 Echinoderm microtubule-associated protein-like 4 Human genes 0.000 description 2
- 101710203446 Echinoderm microtubule-associated protein-like 4 Proteins 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 201000009040 Epidermolytic Hyperkeratosis Diseases 0.000 description 2
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 2
- 208000036566 Erythroleukaemia Diseases 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 101150009057 JAK2 gene Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100323015 Mus musculus Alk gene Proteins 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical class [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 101100517381 Rattus norvegicus Ntrk1 gene Proteins 0.000 description 2
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- GOOHAUXETOMSMM-VKHMYHEASA-N S-propylene oxide Chemical compound C[C@H]1CO1 GOOHAUXETOMSMM-VKHMYHEASA-N 0.000 description 2
- 101100537955 Schizosaccharomyces pombe (strain 972 / ATCC 24843) trk1 gene Proteins 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 208000009621 actinic keratosis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000021841 acute erythroid leukemia Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 201000005188 adrenal gland cancer Diseases 0.000 description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 238000003016 alphascreen Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- WDECIBYCCFPHNR-UHFFFAOYSA-N chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- VPUGDVKSAQVFFS-UHFFFAOYSA-N coronene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3)C4=C4C3=CC=C(C=C3)C4=C2C3=C1 VPUGDVKSAQVFFS-UHFFFAOYSA-N 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 201000003914 endometrial carcinoma Diseases 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 201000010260 leiomyoma Diseases 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- GBROPGWFBFCKAG-UHFFFAOYSA-N picene Chemical compound C1=CC2=C3C=CC=CC3=CC=C2C2=C1C1=CC=CC=C1C=C2 GBROPGWFBFCKAG-UHFFFAOYSA-N 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical class [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- GLQWRXYOTXRDNH-UHFFFAOYSA-N thiophen-2-amine Chemical compound NC1=CC=CS1 GLQWRXYOTXRDNH-UHFFFAOYSA-N 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- ADCVMZFALAHVRG-SSDOTTSWSA-N (2r)-1-(2-fluorophenyl)propan-2-ol Chemical compound C[C@@H](O)CC1=CC=CC=C1F ADCVMZFALAHVRG-SSDOTTSWSA-N 0.000 description 1
- NYVQQTOGYLBBDQ-ZCFIWIBFSA-N (2r)-1-thiophen-2-ylpropan-2-amine Chemical compound C[C@@H](N)CC1=CC=CS1 NYVQQTOGYLBBDQ-ZCFIWIBFSA-N 0.000 description 1
- AYIYPHDKKVWZKI-LJTMIZJLSA-N (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol;piperazine Chemical compound C1CNCCN1.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO AYIYPHDKKVWZKI-LJTMIZJLSA-N 0.000 description 1
- MMNNITBHHOPZKJ-LURJTMIESA-N (2s)-1-(2,3-difluoro-5,6-dimethoxyphenyl)propan-2-amine Chemical compound COC1=CC(F)=C(F)C(C[C@H](C)N)=C1OC MMNNITBHHOPZKJ-LURJTMIESA-N 0.000 description 1
- LATVFYDIBMDBSY-QMMMGPOBSA-N (2s)-1-(2,5-dimethoxyphenyl)propan-2-amine Chemical compound COC1=CC=C(OC)C(C[C@H](C)N)=C1 LATVFYDIBMDBSY-QMMMGPOBSA-N 0.000 description 1
- IQHHOHJDIZRBGM-ZETCQYMHSA-N (2s)-1-(2-chlorophenyl)propan-2-amine Chemical compound C[C@H](N)CC1=CC=CC=C1Cl IQHHOHJDIZRBGM-ZETCQYMHSA-N 0.000 description 1
- GDSXNLDTQFFIEU-ZETCQYMHSA-N (2s)-1-(2-fluorophenyl)propan-2-amine Chemical compound C[C@H](N)CC1=CC=CC=C1F GDSXNLDTQFFIEU-ZETCQYMHSA-N 0.000 description 1
- HEQRYQONNHFDHG-TZSSRYMLSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1 HEQRYQONNHFDHG-TZSSRYMLSA-N 0.000 description 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical compound C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- APQIUTYORBAGEZ-UHFFFAOYSA-N 1,1-dibromoethane Chemical compound CC(Br)Br APQIUTYORBAGEZ-UHFFFAOYSA-N 0.000 description 1
- WWAOVLXLTJXDGS-UHFFFAOYSA-N 1,2-difluoro-4,5-dimethoxybenzene Chemical compound COC1=CC(F)=C(F)C=C1OC WWAOVLXLTJXDGS-UHFFFAOYSA-N 0.000 description 1
- 150000004057 1,4-benzoquinones Chemical class 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- LQRQTYOYXPEWJR-UHFFFAOYSA-N 1-(1-benzothiophen-2-yl)propan-2-amine Chemical compound C1=CC=C2SC(CC(N)C)=CC2=C1 LQRQTYOYXPEWJR-UHFFFAOYSA-N 0.000 description 1
- VREKNASEWSOAKF-UHFFFAOYSA-N 1-(3,5-dimethylthiophen-2-yl)propan-2-amine Chemical compound CC(N)CC=1SC(C)=CC=1C VREKNASEWSOAKF-UHFFFAOYSA-N 0.000 description 1
- SECJGXRWRBYMRR-UHFFFAOYSA-N 1-(4,5-dimethylthiophen-2-yl)propan-2-amine Chemical compound CC(N)CC1=CC(C)=C(C)S1 SECJGXRWRBYMRR-UHFFFAOYSA-N 0.000 description 1
- DITPQAYICZTABK-UHFFFAOYSA-N 1-(4-methylthiophen-2-yl)propan-2-amine Chemical compound CC(N)CC1=CC(C)=CS1 DITPQAYICZTABK-UHFFFAOYSA-N 0.000 description 1
- ZXWPFZOPOVYZGE-UHFFFAOYSA-N 1-(5-ethylthiophen-2-yl)propan-2-amine Chemical compound CCC1=CC=C(CC(C)N)S1 ZXWPFZOPOVYZGE-UHFFFAOYSA-N 0.000 description 1
- IOUDYORIRJOYKC-UHFFFAOYSA-N 1-(5-phenylthiophen-2-yl)propan-2-amine Chemical compound S1C(CC(N)C)=CC=C1C1=CC=CC=C1 IOUDYORIRJOYKC-UHFFFAOYSA-N 0.000 description 1
- XSMLLZPSNLQCQU-UHFFFAOYSA-N 1-bromo-2,3,5-trifluorobenzene Chemical compound FC1=CC(F)=C(F)C(Br)=C1 XSMLLZPSNLQCQU-UHFFFAOYSA-N 0.000 description 1
- QSSXJPIWXQTSIX-UHFFFAOYSA-N 1-bromo-2-methylbenzene Chemical compound CC1=CC=CC=C1Br QSSXJPIWXQTSIX-UHFFFAOYSA-N 0.000 description 1
- YXTCBTSPHSNDHD-UHFFFAOYSA-N 1-bromo-3,4-difluoro-2-methylbenzene Chemical compound CC1=C(Br)C=CC(F)=C1F YXTCBTSPHSNDHD-UHFFFAOYSA-N 0.000 description 1
- QDCBSSUCEUMLGC-UHFFFAOYSA-N 1-bromo-4-fluoro-2-iodobenzene Chemical compound FC1=CC=C(Br)C(I)=C1 QDCBSSUCEUMLGC-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
- NYVQQTOGYLBBDQ-UHFFFAOYSA-N 1-thiophen-2-ylpropan-2-amine Chemical compound CC(N)CC1=CC=CS1 NYVQQTOGYLBBDQ-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- MFJCPDOGFAYSTF-UHFFFAOYSA-N 1H-isochromene Chemical compound C1=CC=C2COC=CC2=C1 MFJCPDOGFAYSTF-UHFFFAOYSA-N 0.000 description 1
- AAQTWLBJPNLKHT-UHFFFAOYSA-N 1H-perimidine Chemical compound N1C=NC2=CC=CC3=CC=CC1=C32 AAQTWLBJPNLKHT-UHFFFAOYSA-N 0.000 description 1
- ODMMNALOCMNQJZ-UHFFFAOYSA-N 1H-pyrrolizine Chemical compound C1=CC=C2CC=CN21 ODMMNALOCMNQJZ-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- XHTBCCLCLVLSPM-UHFFFAOYSA-N 2,3-dimethyl-5-(2-nitroprop-1-enyl)thiophene Chemical compound [O-][N+](=O)C(C)=CC1=CC(C)=C(C)S1 XHTBCCLCLVLSPM-UHFFFAOYSA-N 0.000 description 1
- MPXDAIBTYWGBSL-UHFFFAOYSA-N 2,4-difluoro-1-methylbenzene Chemical compound CC1=CC=C(F)C=C1F MPXDAIBTYWGBSL-UHFFFAOYSA-N 0.000 description 1
- ISBWMRUMUWKUKJ-UHFFFAOYSA-N 2-(2-nitroprop-1-enyl)-5-phenylthiophene Chemical compound S1C(C=C(C)[N+]([O-])=O)=CC=C1C1=CC=CC=C1 ISBWMRUMUWKUKJ-UHFFFAOYSA-N 0.000 description 1
- DSBBLYKVMXLGGE-UHFFFAOYSA-N 2-(4-chloro-2-methoxypyridin-3-yl)-6-[2-(1,1-dioxo-1,4-thiazinan-4-yl)ethyl]-3h-pyrrolo[3,4-f]benzimidazole-5,7-dione Chemical compound COC1=NC=CC(Cl)=C1C(NC1=C2)=NC1=CC1=C2C(=O)N(CCN2CCS(=O)(=O)CC2)C1=O DSBBLYKVMXLGGE-UHFFFAOYSA-N 0.000 description 1
- LVBHQDMOMAWUNV-LBPRGKRZSA-N 2-(4-chloro-2-methoxypyridin-3-yl)-6-[2-[(2s)-2-methylpyrrolidin-1-yl]ethyl]-3h-pyrrolo[3,4-f]benzimidazole-5,7-dione Chemical compound COC1=NC=CC(Cl)=C1C(NC1=C2)=NC1=CC1=C2C(=O)N(CCN2[C@H](CCC2)C)C1=O LVBHQDMOMAWUNV-LBPRGKRZSA-N 0.000 description 1
- CECNWJPVJBOKLW-UHFFFAOYSA-N 2-(4-chloro-2-oxo-1H-pyridin-3-yl)-6-[2-(dimethylamino)ethyl]-3H-pyrrolo[3,4-f]benzimidazole-5,7-dione hydrochloride Chemical compound Cl.N1C=2C=C3C(=O)N(CCN(C)C)C(=O)C3=CC=2N=C1C1=C(Cl)C=CNC1=O CECNWJPVJBOKLW-UHFFFAOYSA-N 0.000 description 1
- UBHMRVNDLOMLAM-LLVKDONJSA-N 2-(4-chloro-2-oxo-1H-pyridin-3-yl)-6-[[(2R)-1-ethylpyrrolidin-2-yl]methyl]-3H-pyrrolo[3,4-f]benzimidazole-5,7-dione Chemical compound CCN1CCC[C@@H]1CN1C(=O)C2=CC(NC(=N3)C=4C(NC=CC=4Cl)=O)=C3C=C2C1=O UBHMRVNDLOMLAM-LLVKDONJSA-N 0.000 description 1
- NERCLSJMFPKGCM-UHFFFAOYSA-N 2-(4-methoxyphenyl)-5-(2-nitroprop-1-enyl)thiophene Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C=C(C)[N+]([O-])=O)S1 NERCLSJMFPKGCM-UHFFFAOYSA-N 0.000 description 1
- HMPLFCAOIJOKGX-WAYWQWQTSA-N 2-[(z)-2-nitroprop-1-enyl]thiophene Chemical compound [O-][N+](=O)C(/C)=C\C1=CC=CS1 HMPLFCAOIJOKGX-WAYWQWQTSA-N 0.000 description 1
- TZBHTUUTVCEESP-UHFFFAOYSA-N 2-[2-oxo-4-(1-thiophen-3-ylpropan-2-ylamino)-1H-pyridin-3-yl]-6-(3-pyrrolidin-1-ylpropyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C1=CNC(=O)C(C=2NC3=CC=4C(=O)N(CCCN5CCCC5)CC=4C=C3N=2)=C1NC(C)CC=1C=CSC=1 TZBHTUUTVCEESP-UHFFFAOYSA-N 0.000 description 1
- BMHNLVBEDWEINE-GOSISDBHSA-N 2-[2-oxo-4-[[(2R)-1-thiophen-2-ylpropan-2-yl]amino]-1H-pyridin-3-yl]-6-(3-pyrrolidin-1-ylpropyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C([C@@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3C(=O)N(CCCN4CCCC4)CC=3C=C2N=1)C1=CC=CS1 BMHNLVBEDWEINE-GOSISDBHSA-N 0.000 description 1
- IQUJBNDZZRJFST-HNNXBMFYSA-N 2-[2-oxo-4-[[(2S)-1-(2,3,5,6-tetrafluorophenyl)propan-2-yl]amino]-1H-pyridin-3-yl]-6-(2-pyrrolidin-1-ylethyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3CN(CCN4CCCC4)C(=O)C=3C=C2N=1)C1=C(F)C(F)=CC(F)=C1F IQUJBNDZZRJFST-HNNXBMFYSA-N 0.000 description 1
- XYRXMRCHOPXBKL-INIZCTEOSA-N 2-[2-oxo-4-[[(2S)-1-(2,3,5-trifluorophenyl)propan-2-yl]amino]-1H-pyridin-3-yl]-6-(2-pyrrolidin-1-ylethyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound O=C1NC=CC(=C1C1=NC=2C(=CC=3CN(C(C3C2)=O)CCN2CCCC2)N1)N[C@H](CC1=C(C(=CC(=C1)F)F)F)C XYRXMRCHOPXBKL-INIZCTEOSA-N 0.000 description 1
- QRKUZIJZPXXCCA-UHFFFAOYSA-N 2-[4-[1-(1-benzothiophen-2-yl)propan-2-ylamino]-2-oxo-1H-pyridin-3-yl]-6-(3-pyrrolidin-1-ylpropyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C=1C2=CC=CC=C2SC=1CC(C)NC=1C=CNC(=O)C=1C(NC1=CC=2C3=O)=NC1=CC=2CN3CCCN1CCCC1 QRKUZIJZPXXCCA-UHFFFAOYSA-N 0.000 description 1
- GWSWOTYWVVIRJR-UHFFFAOYSA-N 2-[4-[1-(2-fluorophenyl)propan-2-ylamino]-2-oxo-1H-pyridin-3-yl]-6-(3-pyrrolidin-1-ylpropyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C1=CNC(=O)C(C=2NC3=CC=4C(=O)N(CCCN5CCCC5)CC=4C=C3N=2)=C1NC(C)CC1=CC=CC=C1F GWSWOTYWVVIRJR-UHFFFAOYSA-N 0.000 description 1
- FQVPXBFOWNYALG-UHFFFAOYSA-N 2-[4-[1-(3-methylthiophen-2-yl)propan-2-ylamino]-2-oxo-1H-pyridin-3-yl]-6-(3-pyrrolidin-1-ylpropyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C1=CNC(=O)C(C=2NC3=CC=4C(=O)N(CCCN5CCCC5)CC=4C=C3N=2)=C1NC(C)CC=1SC=CC=1C FQVPXBFOWNYALG-UHFFFAOYSA-N 0.000 description 1
- NZTUUYBALPIAQO-UHFFFAOYSA-N 2-[4-[1-(5-ethylthiophen-2-yl)propan-2-ylamino]-2-oxo-1H-pyridin-3-yl]-6-(3-pyrrolidin-1-ylpropyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound S1C(CC)=CC=C1CC(C)NC1=C(C=2NC3=CC=4C(=O)N(CCCN5CCCC5)CC=4C=C3N=2)C(=O)NC=C1 NZTUUYBALPIAQO-UHFFFAOYSA-N 0.000 description 1
- KFULNLVIGSBTKN-KRWDZBQOSA-N 2-[4-[[(2S)-1-(2,3-difluoro-5,6-dimethoxyphenyl)propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-6-(2-pyrrolidin-1-ylethyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound COC1=CC(F)=C(F)C(C[C@H](C)NC2=C(C(=O)NC=C2)C=2NC3=CC=4CN(CCN5CCCC5)C(=O)C=4C=C3N=2)=C1OC KFULNLVIGSBTKN-KRWDZBQOSA-N 0.000 description 1
- WZKLLBCQTTULKG-IBGZPJMESA-N 2-[4-[[(2S)-1-(2,5-dimethoxyphenyl)propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-6-(2-pyrrolidin-1-ylethyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound COC1=CC=C(OC)C(C[C@H](C)NC2=C(C(=O)NC=C2)C=2NC3=CC=4CN(CCN5CCCC5)C(=O)C=4C=C3N=2)=C1 WZKLLBCQTTULKG-IBGZPJMESA-N 0.000 description 1
- ZJBSZSLGQJIYJL-KRWDZBQOSA-N 2-[4-[[(2S)-1-(2-chlorophenyl)propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-6-(2-pyrrolidin-1-ylethyl)-3H-pyrrolo[3,4-f]benzimidazole-5,7-dione Chemical compound C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3C(=O)N(CCN4CCCC4)C(=O)C=3C=C2N=1)C1=CC=CC=C1Cl ZJBSZSLGQJIYJL-KRWDZBQOSA-N 0.000 description 1
- RMGFYZBVZNAAAX-FQEVSTJZSA-N 2-[4-[[(2S)-1-(2-ethylphenyl)propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-6-(2-pyrrolidin-1-ylethyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound CCC1=CC=CC=C1C[C@H](C)NC1=C(C=2NC3=CC=4CN(CCN5CCCC5)C(=O)C=4C=C3N=2)C(=O)NC=C1 RMGFYZBVZNAAAX-FQEVSTJZSA-N 0.000 description 1
- PCRTUUVQBUJOKB-SFHVURJKSA-N 2-[4-[[(2S)-1-(2-fluorophenyl)propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-6-(2-pyrrolidin-1-ylethyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3CN(CCN4CCCC4)C(=O)C=3C=C2N=1)C1=CC=CC=C1F PCRTUUVQBUJOKB-SFHVURJKSA-N 0.000 description 1
- QBUHJRVCCUHUEI-KRWDZBQOSA-N 2-[4-[[(2S)-1-(2-fluorophenyl)propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-6-(2-pyrrolidin-1-ylethyl)-3H-pyrrolo[3,4-f]benzimidazole-5,7-dione Chemical compound C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3C(=O)N(CCN4CCCC4)C(=O)C=3C=C2N=1)C1=CC=CC=C1F QBUHJRVCCUHUEI-KRWDZBQOSA-N 0.000 description 1
- TYLAMDQWJPJVCN-KRWDZBQOSA-N 2-[4-[[(2S)-1-(3,4-difluoro-2-methylphenyl)propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-6-(2-pyrrolidin-1-ylethyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3CN(CCN4CCCC4)C(=O)C=3C=C2N=1)C1=CC=C(F)C(F)=C1C TYLAMDQWJPJVCN-KRWDZBQOSA-N 0.000 description 1
- GSAJGOBYFQZCPA-HNNXBMFYSA-N 2-[4-[[(2S)-1-(3,4-difluoro-2-methylphenyl)propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-6-[2-(dimethylamino)ethyl]-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3CN(CCN(C)C)C(=O)C=3C=C2N=1)C1=CC=C(F)C(F)=C1C GSAJGOBYFQZCPA-HNNXBMFYSA-N 0.000 description 1
- WTXAEXXJOFLBDR-KRWDZBQOSA-N 2-[4-[[(2S)-1-(3,5-difluoro-2-methylphenyl)propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-6-(2-pyrrolidin-1-ylethyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3CN(CCN4CCCC4)C(=O)C=3C=C2N=1)C1=CC(F)=CC(F)=C1C WTXAEXXJOFLBDR-KRWDZBQOSA-N 0.000 description 1
- BVZMHJFRPKPOBR-HNNXBMFYSA-N 2-[4-[[(2S)-1-(3,5-difluoro-2-methylphenyl)propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-6-[2-(dimethylamino)ethyl]-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3CN(CCN(C)C)C(=O)C=3C=C2N=1)C1=CC(F)=CC(F)=C1C BVZMHJFRPKPOBR-HNNXBMFYSA-N 0.000 description 1
- YMSMPQVENWYRFP-SFHVURJKSA-N 2-[4-[[(2S)-1-(5-fluoro-2-methoxyphenyl)propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-6-(2-pyrrolidin-1-ylethyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound COC1=CC=C(F)C=C1C[C@H](C)NC1=C(C=2NC3=CC=4CN(CCN5CCCC5)C(=O)C=4C=C3N=2)C(=O)NC=C1 YMSMPQVENWYRFP-SFHVURJKSA-N 0.000 description 1
- XQBHPENVXDRPMV-ZDUSSCGKSA-N 2-[4-[[(2S)-1-(5-fluoro-2-methylphenyl)propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-5,6-dihydro-3H-pyrrolo[3,4-f]benzimidazol-7-one Chemical compound C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3CNC(=O)C=3C=C2N=1)C1=CC(F)=CC=C1C XQBHPENVXDRPMV-ZDUSSCGKSA-N 0.000 description 1
- YRWGDGJFJVDJFG-IBGZPJMESA-N 2-[4-[[(2S)-1-(5-fluoro-2-methylphenyl)propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-8-methyl-6-(2-pyrrolidin-1-ylethyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3CN(CCN4CCCC4)C(=O)C=3C(C)=C2N=1)C1=CC(F)=CC=C1C YRWGDGJFJVDJFG-IBGZPJMESA-N 0.000 description 1
- BIQRDGGAPMGRFN-FQEVSTJZSA-N 2-[4-[[(2S)-1-(5-methoxy-2-methylphenyl)propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-6-(2-pyrrolidin-1-ylethyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound COC1=CC=C(C)C(C[C@H](C)NC2=C(C(=O)NC=C2)C=2NC3=CC=4CN(CCN5CCCC5)C(=O)C=4C=C3N=2)=C1 BIQRDGGAPMGRFN-FQEVSTJZSA-N 0.000 description 1
- HTSHGUSGNITFGN-LMOVPXPDSA-N 2-[4-[[(2S)-1-(furan-2-yl)propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-6-(2-pyrrolidin-1-ylethyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3CN(CCN4CCCC4)C(=O)C=3C=C2N=1)C1=CC=CO1 HTSHGUSGNITFGN-LMOVPXPDSA-N 0.000 description 1
- CKDMJDZMRXJQSW-IBGZPJMESA-N 2-[4-[[(2S)-1-[2-methyl-5-(trifluoromethyl)phenyl]propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-6-(2-morpholin-4-ylethyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3CN(CCN4CCOCC4)C(=O)C=3C=C2N=1)C1=CC(C(F)(F)F)=CC=C1C CKDMJDZMRXJQSW-IBGZPJMESA-N 0.000 description 1
- XLSZCNCQCYTILV-IBGZPJMESA-N 2-[4-[[(2S)-1-[2-methyl-5-(trifluoromethyl)phenyl]propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-6-(2-pyrrolidin-1-ylethyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3CN(CCN4CCCC4)C(=O)C=3C=C2N=1)C1=CC(C(F)(F)F)=CC=C1C XLSZCNCQCYTILV-IBGZPJMESA-N 0.000 description 1
- HDGNVLGFCQHDLP-NRFANRHFSA-N 2-[4-[[(2S)-1-[5-(dimethylamino)-2-methylphenyl]propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-6-(2-pyrrolidin-1-ylethyl)-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3CN(CCN4CCCC4)C(=O)C=3C=C2N=1)C1=CC(N(C)C)=CC=C1C HDGNVLGFCQHDLP-NRFANRHFSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- DWCGNRKFLRLWCJ-UHFFFAOYSA-N 2-bromo-1,4-dimethoxybenzene Chemical compound COC1=CC=C(OC)C(Br)=C1 DWCGNRKFLRLWCJ-UHFFFAOYSA-N 0.000 description 1
- FOCCSIJMXBTKHD-UHFFFAOYSA-N 2-bromo-1-chloro-4-fluorobenzene Chemical compound FC1=CC=C(Cl)C(Br)=C1 FOCCSIJMXBTKHD-UHFFFAOYSA-N 0.000 description 1
- TWWUWLMGYSLODU-UHFFFAOYSA-N 2-bromo-1-methyl-4-(trifluoromethyl)benzene Chemical compound CC1=CC=C(C(F)(F)F)C=C1Br TWWUWLMGYSLODU-UHFFFAOYSA-N 0.000 description 1
- YYJBWYBULYUKMR-UHFFFAOYSA-N 2-bromo-3-methylthiophene Chemical compound CC=1C=CSC=1Br YYJBWYBULYUKMR-UHFFFAOYSA-N 0.000 description 1
- JIQXVIJARQLCOY-UHFFFAOYSA-N 2-bromo-4-fluoro-1-methoxybenzene Chemical compound COC1=CC=C(F)C=C1Br JIQXVIJARQLCOY-UHFFFAOYSA-N 0.000 description 1
- BMXBTIPHUSHTEH-UHFFFAOYSA-N 2-ethyl-5-(2-nitroprop-1-enyl)thiophene Chemical compound CCC1=CC=C(C=C(C)[N+]([O-])=O)S1 BMXBTIPHUSHTEH-UHFFFAOYSA-N 0.000 description 1
- IWTFOFMTUOBLHG-UHFFFAOYSA-N 2-methoxypyridine Chemical compound COC1=CC=CC=N1 IWTFOFMTUOBLHG-UHFFFAOYSA-N 0.000 description 1
- SFOYVCFXQMPORA-UHFFFAOYSA-N 2-methyl-5-(2-nitroprop-1-enyl)thiophene Chemical compound [O-][N+](=O)C(C)=CC1=CC=C(C)S1 SFOYVCFXQMPORA-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- XQQBUAPQHNYYRS-UHFFFAOYSA-N 2-methylthiophene Chemical compound CC1=CC=CS1 XQQBUAPQHNYYRS-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- IISXXYSSIKCYFQ-UHFFFAOYSA-N 3,5-difluoro-2-(trifluoromethyl)aniline Chemical compound NC1=CC(F)=CC(F)=C1C(F)(F)F IISXXYSSIKCYFQ-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- YHAFCGSUIAFUCX-UHFFFAOYSA-N 3-bromo-1,2,4,5-tetrafluorobenzene Chemical compound FC1=CC(F)=C(F)C(Br)=C1F YHAFCGSUIAFUCX-UHFFFAOYSA-N 0.000 description 1
- QUBJDMPBDURTJT-UHFFFAOYSA-N 3-chlorothiophene Chemical compound ClC=1C=CSC=1 QUBJDMPBDURTJT-UHFFFAOYSA-N 0.000 description 1
- RRUDMHNAMZFNEK-UHFFFAOYSA-N 3-iodo-4-methylaniline Chemical compound CC1=CC=C(N)C=C1I RRUDMHNAMZFNEK-UHFFFAOYSA-N 0.000 description 1
- RFSKGCVUDQRZSD-UHFFFAOYSA-N 3-methoxythiophene Chemical compound COC=1C=CSC=1 RFSKGCVUDQRZSD-UHFFFAOYSA-N 0.000 description 1
- XAIOJTJIVZHGIA-FNORWQNLSA-N 3-methyl-2-[(e)-2-nitroprop-1-enyl]thiophene Chemical compound [O-][N+](=O)C(/C)=C/C=1SC=CC=1C XAIOJTJIVZHGIA-FNORWQNLSA-N 0.000 description 1
- ZREYEONHFGJPJC-UHFFFAOYSA-N 3h-pyrazolo[3,4-c]isoquinoline Chemical class C1=CC=C2C3=CNN=C3N=CC2=C1 ZREYEONHFGJPJC-UHFFFAOYSA-N 0.000 description 1
- YTJWBAMDRDWGEG-UHFFFAOYSA-N 4,5-diaminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1N YTJWBAMDRDWGEG-UHFFFAOYSA-N 0.000 description 1
- HOCPDSKONPQIQM-UHFFFAOYSA-N 4-(2-bromoethyl)isoindole-1,3-dione Chemical compound BrCCC1=CC=CC2=C1C(=O)NC2=O HOCPDSKONPQIQM-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- UIHHZVBAWSBLNK-UHFFFAOYSA-N 4-amino-6-methoxycarbonyl-2-methyl-3-nitrobenzoic acid Chemical compound COC(=O)C1=CC(N)=C([N+]([O-])=O)C(C)=C1C(O)=O UIHHZVBAWSBLNK-UHFFFAOYSA-N 0.000 description 1
- GQBONCZDJQXPLV-UHFFFAOYSA-N 4-aminoisoindole-1,3-dione Chemical compound NC1=CC=CC2=C1C(=O)NC2=O GQBONCZDJQXPLV-UHFFFAOYSA-N 0.000 description 1
- ANENLORAJJKWAA-UHFFFAOYSA-N 4-bromoisoindole-1,3-dione Chemical compound BrC1=CC=CC2=C1C(=O)NC2=O ANENLORAJJKWAA-UHFFFAOYSA-N 0.000 description 1
- ZIOGCIPQDRCAKY-UHFFFAOYSA-N 4-chloro-2-iodo-1-methylbenzene Chemical compound CC1=CC=C(Cl)C=C1I ZIOGCIPQDRCAKY-UHFFFAOYSA-N 0.000 description 1
- RTBLBWFHGXSBPO-UHFFFAOYSA-N 4-chloro-6-(1-methylpiperidin-4-yl)-2-[2-oxo-4-(1-thiophen-2-ylpropan-2-ylamino)-1H-pyridin-3-yl]-1,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C1=CNC(=O)C(C=2NC3=CC=4C(=O)N(C5CCN(C)CC5)CC=4C(Cl)=C3N=2)=C1NC(C)CC1=CC=CS1 RTBLBWFHGXSBPO-UHFFFAOYSA-N 0.000 description 1
- GNBKAOHTTIVAMT-UHFFFAOYSA-N 4-iodo-2-methoxypyridine-3-carbaldehyde Chemical compound COC1=NC=CC(I)=C1C=O GNBKAOHTTIVAMT-UHFFFAOYSA-N 0.000 description 1
- JBORNNNGTJSTLC-UHFFFAOYSA-N 4-methoxy-1-methyl-2-nitrobenzene Chemical compound COC1=CC=C(C)C([N+]([O-])=O)=C1 JBORNNNGTJSTLC-UHFFFAOYSA-N 0.000 description 1
- VOAFPAITNALWMA-UHFFFAOYSA-N 4-methyl-2-(2-nitroprop-1-enyl)thiophene Chemical compound [O-][N+](=O)C(C)=CC1=CC(C)=CS1 VOAFPAITNALWMA-UHFFFAOYSA-N 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- LRCMWULCRXYKRP-UHFFFAOYSA-N 5-amino-2-(1-methylpiperidin-4-yl)-6-nitroisoindole-1,3-dione Chemical compound C1CN(C)CCC1N1C(=O)C2=CC([N+]([O-])=O)=C(N)C=C2C1=O LRCMWULCRXYKRP-UHFFFAOYSA-N 0.000 description 1
- QQWUGDVOUVUTOY-UHFFFAOYSA-N 5-chloro-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)C(C)C QQWUGDVOUVUTOY-UHFFFAOYSA-N 0.000 description 1
- FGRXHYJKYXMUNL-INIZCTEOSA-N 6-(2-morpholin-4-ylethyl)-2-[2-oxo-4-[[(2S)-1-(2,3,5-trifluorophenyl)propan-2-yl]amino]-1H-pyridin-3-yl]-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3CN(CCN4CCOCC4)C(=O)C=3C=C2N=1)C1=CC(F)=CC(F)=C1F FGRXHYJKYXMUNL-INIZCTEOSA-N 0.000 description 1
- HZERLNPBDIANHA-SFHVURJKSA-N 6-[2-(3,3-difluoropyrrolidin-1-yl)ethyl]-2-[4-[[(2S)-1-(5-fluoro-2-methylphenyl)propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3CN(CCN4CC(F)(F)CC4)C(=O)C=3C=C2N=1)C1=CC(F)=CC=C1C HZERLNPBDIANHA-SFHVURJKSA-N 0.000 description 1
- VPFBEOATBHHNQX-AWEZNQCLSA-N 6-[2-(dimethylamino)ethyl]-2-[2-oxo-4-[[(2S)-1-(2,3,5-trifluorophenyl)propan-2-yl]amino]-1H-pyridin-3-yl]-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3CN(CCN(C)C)C(=O)C=3C=C2N=1)C1=CC(F)=CC(F)=C1F VPFBEOATBHHNQX-AWEZNQCLSA-N 0.000 description 1
- MYAZYYDQJHSCFK-KRWDZBQOSA-N 6-[2-(dimethylamino)ethyl]-2-[4-[[(2S)-1-(5-fluoro-2-methylphenyl)propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3CN(CCN(C)C)C(=O)C=3C=C2N=1)C1=CC(F)=CC=C1C MYAZYYDQJHSCFK-KRWDZBQOSA-N 0.000 description 1
- LUZAWYKNKAJONF-KRWDZBQOSA-N 6-[2-(dimethylamino)ethyl]-2-[4-[[(2S)-1-[2-methyl-5-(trifluoromethyl)phenyl]propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3CN(CCN(C)C)C(=O)C=3C=C2N=1)C1=CC(C(F)(F)F)=CC=C1C LUZAWYKNKAJONF-KRWDZBQOSA-N 0.000 description 1
- QDCDUYFGWZXAKO-DLBZAZTESA-N 6-[2-[(2R)-2-methylpyrrolidin-1-yl]ethyl]-2-[2-oxo-4-[[(2S)-1-(2,3,5-trifluorophenyl)propan-2-yl]amino]-1H-pyridin-3-yl]-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound C([C@H](C)NC1=C(C(=O)NC=C1)C=1NC2=CC=3CN(CCN4[C@@H](CCC4)C)C(=O)C=3C=C2N=1)C1=CC(F)=CC(F)=C1F QDCDUYFGWZXAKO-DLBZAZTESA-N 0.000 description 1
- OGSLKVLDJFALCD-ICSRJNTNSA-N 6-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2-[4-[[(2S)-1-(3-methylthiophen-2-yl)propan-2-yl]amino]-2-oxo-1H-pyridin-3-yl]-3,5-dihydropyrrolo[3,4-f]benzimidazol-7-one Chemical compound CCN1CCC[C@H]1CN1C(=O)C2=CC(NC(=N3)C=4C(NC=CC=4N[C@@H](C)CC4=C(C=CS4)C)=O)=C3C=C2C1 OGSLKVLDJFALCD-ICSRJNTNSA-N 0.000 description 1
- JXVAYKMGPCWIAG-UHFFFAOYSA-N 8-chloro-2-(4-chloro-2-oxo-1H-pyridin-3-yl)-6-(1-methylpiperidin-4-yl)-3H-pyrrolo[3,4-f]benzimidazole-5,7-dione Chemical compound C1CN(C)CCC1N1C(=O)C2=C(Cl)C(N=C(N3)C=4C(NC=CC=4Cl)=O)=C3C=C2C1=O JXVAYKMGPCWIAG-UHFFFAOYSA-N 0.000 description 1
- MELMAJZFVZZQIJ-UHFFFAOYSA-N 8-chloro-2-[4-[[3-(2,4-dimethylphenoxy)-2-hydroxypropyl]amino]-2-oxo-1H-pyridin-3-yl]-6-(1-methylpiperidin-4-yl)-3H-pyrrolo[3,4-f]benzimidazole-5,7-dione Chemical compound C1CN(C)CCC1N1C(=O)C2=C(Cl)C(N=C(N3)C=4C(NC=CC=4NCC(O)COC=4C(=CC(C)=CC=4)C)=O)=C3C=C2C1=O MELMAJZFVZZQIJ-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 229940126069 ALK kinase inhibitor Drugs 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000857945 Anita Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- QLRRUWXMMVXORS-UHFFFAOYSA-N Augustine Natural products C12=CC=3OCOC=3C=C2CN2C3CC(OC)C4OC4C31CC2 QLRRUWXMMVXORS-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000023095 Autosomal dominant epidermolytic ichthyosis Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000004358 Butane-1, 3-diol Substances 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- KKOQBLFUMNKLAH-HFEGYEGKSA-N ClC1=C(C=CC=C1)C[C@@H](C)O.ClC1=C(C=CC=C1)C[C@@H](C)O Chemical compound ClC1=C(C=CC=C1)C[C@@H](C)O.ClC1=C(C=CC=C1)C[C@@H](C)O KKOQBLFUMNKLAH-HFEGYEGKSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 101100010343 Drosophila melanogaster lobo gene Proteins 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000017347 Erythrokeratoderma Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 108010002459 HIV Integrase Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 1
- MCAHMSDENAOJFZ-UHFFFAOYSA-N Herbimycin A Natural products N1C(=O)C(C)=CC=CC(OC)C(OC(N)=O)C(C)=CC(C)C(OC)C(OC)CC(C)C(OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 description 1
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 1
- 101150026109 INSR gene Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100039137 Insulin receptor-related protein Human genes 0.000 description 1
- 101150069380 JAK3 gene Proteins 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 238000003720 Kinase-Glo Luminescent Kinase Assay Methods 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 208000036631 Metastatic pain Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100268648 Mus musculus Abl1 gene Proteins 0.000 description 1
- 101100325641 Mus musculus Aurka gene Proteins 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 101150038994 PDGFRA gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 101150001535 SRC gene Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 108010017622 Somatomedin Receptors Proteins 0.000 description 1
- 102000004584 Somatomedin Receptors Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- SLGBZMMZGDRARJ-UHFFFAOYSA-N Triphenylene Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC=C3C2=C1 SLGBZMMZGDRARJ-UHFFFAOYSA-N 0.000 description 1
- 102100033080 Tropomyosin alpha-3 chain Human genes 0.000 description 1
- 101710091952 Tropomyosin alpha-3 chain Proteins 0.000 description 1
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- QVXFGVVYTKZLJN-KHPPLWFESA-N [(z)-hexadec-7-enyl] acetate Chemical compound CCCCCCCC\C=C/CCCCCCOC(C)=O QVXFGVVYTKZLJN-KHPPLWFESA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- JDPAVWAQGBGGHD-UHFFFAOYSA-N aceanthrylene Chemical group C1=CC=C2C(C=CC3=CC=C4)=C3C4=CC2=C1 JDPAVWAQGBGGHD-UHFFFAOYSA-N 0.000 description 1
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- SQFPKRNUGBRTAR-UHFFFAOYSA-N acephenanthrylene Chemical group C1=CC(C=C2)=C3C2=CC2=CC=CC=C2C3=C1 SQFPKRNUGBRTAR-UHFFFAOYSA-N 0.000 description 1
- 150000003869 acetamides Chemical class 0.000 description 1
- HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000005360 alkyl sulfoxide group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000005124 aminocycloalkyl group Chemical group 0.000 description 1
- 238000012440 amplified luminescent proximity homogeneous assay Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000025164 anoikis Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001621 anti-mitogenic effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- BVUSIQTYUVWOSX-UHFFFAOYSA-N arsindole Chemical compound C1=CC=C2[As]C=CC2=C1 BVUSIQTYUVWOSX-UHFFFAOYSA-N 0.000 description 1
- KNNXFYIMEYKHBZ-UHFFFAOYSA-N as-indacene Chemical compound C1=CC2=CC=CC2=C2C=CC=C21 KNNXFYIMEYKHBZ-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 150000004768 bromobenzenes Chemical class 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000008356 dextrose and sodium chloride injection Substances 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 210000002451 diencephalon Anatomy 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000105 enteric nervous system Anatomy 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 208000033286 epidermolytic ichthyosis Diseases 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 208000018212 fibroblastic neoplasm Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- CNUDBTRUORMMPA-UHFFFAOYSA-N formylthiophene Chemical class O=CC1=CC=CS1 CNUDBTRUORMMPA-UHFFFAOYSA-N 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- MCAHMSDENAOJFZ-BVXDHVRPSA-N herbimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-BVXDHVRPSA-N 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- QSQIGGCOCHABAP-UHFFFAOYSA-N hexacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC6=CC=CC=C6C=C5C=C4C=C3C=C21 QSQIGGCOCHABAP-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid group Chemical group C(CCCCC)(=O)O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- PKIFBGYEEVFWTJ-UHFFFAOYSA-N hexaphene Chemical compound C1=CC=C2C=C3C4=CC5=CC6=CC=CC=C6C=C5C=C4C=CC3=CC2=C1 PKIFBGYEEVFWTJ-UHFFFAOYSA-N 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 150000002467 indacenes Chemical class 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 108010054372 insulin receptor-related receptor Proteins 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940043363 multi-kinase inhibitor Drugs 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000933 neural crest Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- HKKDKUMUWRTAIA-UHFFFAOYSA-N nitridooxidocarbon(.) Chemical compound [O]C#N HKKDKUMUWRTAIA-UHFFFAOYSA-N 0.000 description 1
- MCSAJNNLRCFZED-UHFFFAOYSA-N nitroethane Chemical compound CC[N+]([O-])=O MCSAJNNLRCFZED-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- PFTXKXWAXWAZBP-UHFFFAOYSA-N octacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC6=CC7=CC8=CC=CC=C8C=C7C=C6C=C5C=C4C=C3C=C21 PFTXKXWAXWAZBP-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- OVPVGJFDFSJUIG-UHFFFAOYSA-N octalene Chemical compound C1=CC=CC=C2C=CC=CC=CC2=C1 OVPVGJFDFSJUIG-UHFFFAOYSA-N 0.000 description 1
- WTFQBTLMPISHTA-UHFFFAOYSA-N octaphene Chemical compound C1=CC=C2C=C(C=C3C4=CC5=CC6=CC7=CC=CC=C7C=C6C=C5C=C4C=CC3=C3)C3=CC2=C1 WTFQBTLMPISHTA-UHFFFAOYSA-N 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- LSQODMMMSXHVCN-UHFFFAOYSA-N ovalene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3C5=C6C(C=C3)=CC=C3C6=C6C(C=C3)=C3)C4=C5C6=C2C3=C1 LSQODMMMSXHVCN-UHFFFAOYSA-N 0.000 description 1
- 201000003733 ovarian melanoma Diseases 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- PMJHHCWVYXUKFD-UHFFFAOYSA-N penta-1,3-diene Chemical compound CC=CC=C PMJHHCWVYXUKFD-UHFFFAOYSA-N 0.000 description 1
- SLIUAWYAILUBJU-UHFFFAOYSA-N pentacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC=CC=C5C=C4C=C3C=C21 SLIUAWYAILUBJU-UHFFFAOYSA-N 0.000 description 1
- GUVXZFRDPCKWEM-UHFFFAOYSA-N pentalene Chemical compound C1=CC2=CC=CC2=C1 GUVXZFRDPCKWEM-UHFFFAOYSA-N 0.000 description 1
- JQQSUOJIMKJQHS-UHFFFAOYSA-N pentaphene Chemical compound C1=CC=C2C=C3C4=CC5=CC=CC=C5C=C4C=CC3=CC2=C1 JQQSUOJIMKJQHS-UHFFFAOYSA-N 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 description 1
- CSHWQDPOILHKBI-UHFFFAOYSA-N peryrene Natural products C1=CC(C2=CC=CC=3C2=C2C=CC=3)=C3C2=CC=CC3=C1 CSHWQDPOILHKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- NQFOGDIWKQWFMN-UHFFFAOYSA-N phenalene Chemical compound C1=CC([CH]C=C2)=C3C2=CC=CC3=C1 NQFOGDIWKQWFMN-UHFFFAOYSA-N 0.000 description 1
- QARVLSVVCXYDNA-UHFFFAOYSA-N phenyl bromide Natural products BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 125000005543 phthalimide group Chemical class 0.000 description 1
- 125000005544 phthalimido group Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 206010035116 pityriasis rubra pilaris Diseases 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- DIJNSQQKNIVDPV-UHFFFAOYSA-N pleiadene Chemical compound C1=C2[CH]C=CC=C2C=C2C=CC=C3[C]2C1=CC=C3 DIJNSQQKNIVDPV-UHFFFAOYSA-N 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical class CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- LNKHTYQPVMAJSF-UHFFFAOYSA-N pyranthrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC3=C(C=CC=C4)C4=CC4=CC=C1C2=C34 LNKHTYQPVMAJSF-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- FMKFBRKHHLWKDB-UHFFFAOYSA-N rubicene Chemical compound C12=CC=CC=C2C2=CC=CC3=C2C1=C1C=CC=C2C4=CC=CC=C4C3=C21 FMKFBRKHHLWKDB-UHFFFAOYSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007905 soft elastic gelatin capsule Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000004360 trifluorophenyl group Chemical group 0.000 description 1
- 125000005580 triphenylene group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 102000015533 trkA Receptor Human genes 0.000 description 1
- 108010064884 trkA Receptor Proteins 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 150000003679 valine derivatives Chemical class 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000008136 water-miscible vehicle Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3803208P | 2008-03-19 | 2008-03-19 | |
| PCT/US2009/001691 WO2009117097A1 (en) | 2008-03-19 | 2009-03-18 | Novel tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2262807T3 true DK2262807T3 (en) | 2015-11-30 |
Family
ID=40814009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09721981.0T DK2262807T3 (en) | 2008-03-19 | 2009-03-18 | NOVEL tyrosine kinase inhibitors |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8815906B2 (enExample) |
| EP (2) | EP2966076A1 (enExample) |
| JP (2) | JP5628145B2 (enExample) |
| CN (1) | CN102036990B (enExample) |
| AU (1) | AU2009226153B2 (enExample) |
| CA (1) | CA2718872C (enExample) |
| DK (1) | DK2262807T3 (enExample) |
| MX (1) | MX2010010272A (enExample) |
| WO (1) | WO2009117097A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2262807T3 (en) * | 2008-03-19 | 2015-11-30 | Chembridge Corp | NOVEL tyrosine kinase inhibitors |
| US9249147B2 (en) * | 2008-03-19 | 2016-02-02 | Chembridge Corporation | Tyrosine kinase inhibitors |
| WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
| SG10201500895XA (en) | 2009-11-05 | 2015-04-29 | Rhizen Pharmaceuticals Sa | Chromen-4-one Derivatives As Kinase Modulators |
| KR102015402B1 (ko) | 2010-05-20 | 2019-08-28 | 어레이 바이오파마 인크. | Trk 키나제 저해제로서의 매크로시클릭 화합물 |
| WO2012037155A2 (en) | 2010-09-13 | 2012-03-22 | Gtx, Inc. | Tyrosine kinase inhibitors |
| RS58326B1 (sr) | 2011-05-04 | 2019-03-29 | Rhizen Pharmaceuticals S A | Nova jedinjenja kao modulatori proteinskih kinaza |
| WO2013074518A1 (en) * | 2011-11-14 | 2013-05-23 | Tesaro, Inc. | Modulating certain tyrosine kinases |
| BR112014026266A2 (pt) | 2012-04-24 | 2017-06-27 | Chugai Pharmaceutical Co Ltd | derivado de quinazolidinadiona |
| BR112014026305A2 (pt) * | 2012-04-24 | 2017-06-27 | Chugai Pharmaceutical Co Ltd | derivado de quinazolidinadiona |
| CN109970742A (zh) | 2012-07-04 | 2019-07-05 | 理森制药股份公司 | 选择性PI3Kδ抑制剂 |
| KR20150123250A (ko) | 2013-03-06 | 2015-11-03 | 제넨테크, 인크. | 암 약물 내성의 치료 및 예방 방법 |
| CN104109168B (zh) * | 2013-04-20 | 2017-02-15 | 山东轩竹医药科技有限公司 | 四并环激酶抑制剂 |
| JP6562908B2 (ja) | 2013-10-11 | 2019-08-21 | ヤンセン バイオファーマ インク． | 置換ヌクレオシド、置換ヌクレオチドおよびその類似体 |
| US10005739B2 (en) | 2013-10-23 | 2018-06-26 | Chugai Seiyaku Kabushiki Kaisha | Quinazolinone and isoquinolinone derivative |
| HRP20200662T1 (hr) * | 2014-02-04 | 2020-10-02 | Astellas Pharma Inc. | Ljekoviti pripravak koji sadrži spoj diamino heterocikličkog karboksamida kao aktivni sastojak |
| WO2015161152A1 (en) * | 2014-04-17 | 2015-10-22 | Amgen Inc. | Polymorphic forms and co-crystals of a c-met inhibitor |
| EP3154589A1 (en) | 2014-06-13 | 2017-04-19 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
| WO2016142835A1 (en) * | 2015-03-10 | 2016-09-15 | Aurigene Discovery Technologies Limited | Therapeutic cyclic compounds as immunomodulators |
| KR20180012853A (ko) | 2015-06-16 | 2018-02-06 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 피페리딘 유도체 및 이의 제조 방법 및 약학적 용도 |
| HUE053067T2 (hu) | 2015-07-16 | 2021-06-28 | Array Biopharma Inc | Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok |
| CN108602890A (zh) | 2015-12-11 | 2018-09-28 | 瑞泽恩制药公司 | 用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法 |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| TWI752098B (zh) | 2016-10-10 | 2022-01-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| US10513515B2 (en) | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| EP3740490A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| CA3087972C (en) | 2018-01-18 | 2023-01-10 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| CA3106239A1 (en) | 2018-07-27 | 2020-01-30 | Biotheryx, Inc. | Bifunctional compounds as cdk modulators |
| JP2022500383A (ja) | 2018-09-10 | 2022-01-04 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物 |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021222150A2 (en) | 2020-04-28 | 2021-11-04 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
| CN116096715A (zh) | 2020-07-06 | 2023-05-09 | 泰科根公司 | 用于精神障碍或精神增强的有益苯并噻吩组合物 |
| CA3187217A1 (en) | 2020-08-06 | 2022-02-10 | Matthew BAGGOTT | 2-aminoindane compounds for mental disorders or enhancement |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| EP0600830A1 (de) * | 1992-11-27 | 1994-06-08 | Ciba-Geigy Ag | Substituierte Derivate von Diaminophthalimid als Protein-Tyrosin-Kinase-Hemmer |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| WO2004063151A2 (en) | 2003-01-03 | 2004-07-29 | Bristol-Myers Squibb Company | Novel tyrosine kinase inhibitors |
| US20060211724A1 (en) | 2003-04-28 | 2006-09-21 | Verschueren Gaston W | Hiv integrase inhibitors |
| AU2004259012C1 (en) * | 2003-07-23 | 2012-08-02 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| US20060235013A1 (en) * | 2005-04-14 | 2006-10-19 | Guy Georges | Tricyclic azole derivatives |
| US20090005396A1 (en) * | 2005-04-27 | 2009-01-01 | Astrazeneca Ab | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain |
| US20080062003A1 (en) * | 2006-08-07 | 2008-03-13 | Christian Paetz | Wireless controllable power control device molded into a power cable |
| US8063225B2 (en) * | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
| WO2008022747A1 (en) * | 2006-08-21 | 2008-02-28 | F. Hoffmann-La Roche Ag | Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents |
| DK2262807T3 (en) * | 2008-03-19 | 2015-11-30 | Chembridge Corp | NOVEL tyrosine kinase inhibitors |
-
2009
- 2009-03-18 DK DK09721981.0T patent/DK2262807T3/en active
- 2009-03-18 AU AU2009226153A patent/AU2009226153B2/en not_active Ceased
- 2009-03-18 US US12/922,891 patent/US8815906B2/en not_active Expired - Fee Related
- 2009-03-18 CN CN200980118256.XA patent/CN102036990B/zh not_active Expired - Fee Related
- 2009-03-18 EP EP15177176.3A patent/EP2966076A1/en not_active Withdrawn
- 2009-03-18 WO PCT/US2009/001691 patent/WO2009117097A1/en not_active Ceased
- 2009-03-18 EP EP09721981.0A patent/EP2262807B1/en not_active Not-in-force
- 2009-03-18 JP JP2011500801A patent/JP5628145B2/ja not_active Expired - Fee Related
- 2009-03-18 CA CA2718872A patent/CA2718872C/en not_active Expired - Fee Related
- 2009-03-18 MX MX2010010272A patent/MX2010010272A/es active IP Right Grant
-
2013
- 2013-01-18 JP JP2013006922A patent/JP2013082744A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2718872C (en) | 2016-09-13 |
| JP5628145B2 (ja) | 2014-11-19 |
| US20130053376A1 (en) | 2013-02-28 |
| AU2009226153A1 (en) | 2009-09-24 |
| JP2013082744A (ja) | 2013-05-09 |
| EP2262807A1 (en) | 2010-12-22 |
| JP2011515397A (ja) | 2011-05-19 |
| CA2718872A1 (en) | 2009-09-24 |
| AU2009226153B2 (en) | 2014-02-20 |
| WO2009117097A1 (en) | 2009-09-24 |
| EP2262807B1 (en) | 2015-08-12 |
| CN102036990A (zh) | 2011-04-27 |
| MX2010010272A (es) | 2011-05-25 |
| US8815906B2 (en) | 2014-08-26 |
| CN102036990B (zh) | 2015-09-30 |
| EP2966076A1 (en) | 2016-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2262807B1 (en) | Novel tyrosine kinase inhibitors | |
| JP7326305B2 (ja) | 医薬化合物 | |
| EP3867263B1 (en) | Proteolysis targeting chimera (protacs) as degraders of smarca2 and/or smarca4 | |
| EP3931188B1 (en) | New isoindolinone substituted indoles and derivatives as ras inhibitors | |
| CN113166153B (zh) | 作为a2a/a2b抑制剂的稠合吡嗪衍生物 | |
| US9273055B2 (en) | Tyrosine kinase inhibitors | |
| JP6318156B2 (ja) | キナーゼをモジュレートするための化合物および方法、ならびにその指標 | |
| EP2066673B1 (en) | Tricyclic compounds and its use as tyrosine kinase modulators | |
| JP6466456B2 (ja) | 抗がん剤としての三環式化合物 | |
| TW202320765A (zh) | 作為kras抑制劑的雜三環化合物 | |
| KR20220100879A (ko) | Fgfr 저해제로서의 이환식 헤테로사이클 | |
| CN112135824A (zh) | 作为免疫调节剂的杂环化合物 | |
| CN115315424A (zh) | 2-甲基-氮杂-喹唑啉 | |
| CN107428760A (zh) | (s)‑n‑(5‑((r)‑2‑(2,5‑二氟苯基)‑吡咯烷‑1‑基)‑吡唑并[1,5‑a]嘧啶‑3‑基)‑3‑羟基吡咯烷‑1‑甲酰胺硫酸氢盐的晶型 | |
| MX2012011045A (es) | Novedosos derivados de indolina sustituidos. | |
| CN107635986A (zh) | 取代的喹喔啉衍生物 | |
| EA029312B1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| TWI915393B (zh) | 作為雄激素受體調節劑的吲哚化合物 | |
| CN108349984A (zh) | 作为perk抑制剂的1-苯基吡咯烷-2-酮的衍生物 | |
| WO2016050171A1 (zh) | 多环类间变性淋巴瘤激酶抑制剂 | |
| TW202220987A (zh) | 經取代雜環化合物及其治療用途 | |
| US9249147B2 (en) | Tyrosine kinase inhibitors | |
| WO2026069240A1 (en) | Piperidine-2, 6-dione derivatives pharmaceutical compounds | |
| CA3269027A1 (en) | Azole derivatives as shp2 inhibitors | |
| HK40100302A (zh) | 作为激酶抑制剂的吲唑类化合物 |